Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Shenzhen Geno-Immune Medical Institute: Clinical Trials & FDA Approval Profile

Shenzhen Geno-Immune Medical Institute (Global / Institutional) sponsors 29 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 10 active protocols (1 recruiting now), 0 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)65.5%
Median Closed Enrollment vs National (145 pts)100 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Shenzhen Geno-Immune Medical Institute
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)29
Active Pipeline (Recruiting Now)10 (1)
Completed vs Stopped Early0 / 19 (65.5%)
Median Closed Actual Enrollment100 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Shenzhen Geno-Immune Medical Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI